Theravance Biopharma, Inc. · NASDAQ:TBPH
Theravance Biopharma — Q2 2025 Earnings Presentation
23 slides from Theravance Biopharma's earnings presentation, Aug 12, 2025
Slide 1: Second Quarter 2025 Financial Results and Business Update
THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners.
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains certain "forward - looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events . Theravance B
Slide 3: Agenda
3 Agenda Opening & Closing Remarks Rick Winningham : Chief Executive Officer Commercial Updates Rhonda Farnum: Senior Vice President, Chief Business Officer TRELEGY & Financial Updates Aziz Sawaf: Senior Vice President, Chief Financial Officer Q&A Team Development & Regulatory Updates Dr. Áine Mille
Slide 4: Strong Financial Position and Cash-Generating YUPELRI Set the Foundation for Near-Term Ampreloxetine Phase 3 Catalyst
4 Strong Financial Position and Cash - Generating YUPELRI ® Set the Foundation for Near - Term Ampreloxetine Phase 3 Catalyst Performance in Second Quarter Driven by Strong Execution and Strategic Transaction 1. In the US, Viatris is leading the commercialization of YUPELRI, and Theravance Biopharma
Slide 5: The Only Once-Daily, Nebulized LAMA Maintenance Medicine for COPD
The Only Once - Daily, Nebulized LAMA Maintenance Medicine for COPD Co - promotion agreement with VIATRIS TM (35% / 65% Profit Share) Rhonda Farnum Senior Vice President, Chief Business Officer COPD, chronic obstructive pulmonary disease; LAMA, long - acting muscarinic antagonist.
Slide 6: Continued Year-over-Year YUPELRI Net Sales Growth in the US
6 Continued Year - over - Year YUPELRI ® Net Sales Growth in the US In the US, Viatris is leading the commercialization of YUPELRI, and Theravance Biopharma co - promotes the product under a profit and loss sharing arrangement (65% to Viatris; 35% to Theravance Biopharma). Net sales increased 22% Q2
Slide 7: Substantial Growth Potential for YUPELRI
7 Substantial Growth Potential for YUPELRI ® 1. Joint VTRS/TBPH Market Research. 2. Addressable patient population quantifies the number of patients within the intended t arg et profile. Source: Joint VTRS/TBPH Market Research. 3. In the US, Viatris is leading the commercialization of YUPELRI, and T
Slide 8: Ampreloxetine
The first once - daily, selective norepinephrine reuptake inhibitor in development to treat symptomatic neurogenic orthostatic hypotension ( nOH ) in patients with multiple system atrophy (MSA) Dr. Áine Miller Senior Vice President, Development AMPRELOXETINE
Slide 9: Ampreloxetine Intended to Target Underlying Physiology of nOH in Patients with MSA
9 Ampreloxetine Intended to Target Underlying Physiology of nOH in Patients with MSA 1. Norcliffe - Kaufmann L, Kaufmann H, Palma JA, et al. Orthostatic heart rate changes in patients with autonomic failure caused b y neurodegenerative synucleinopathies . Ann Neurol 2018;83:522 - 531. 2. Reflects Th
Slide 10: CYPRESS Design and Execution Optimizes Probability of Success
10 CYPRESS Design and Execution Optimizes Probability of Success Protocol Design Protocol replicates the successes of the 0170 MSA cohort Composite OHSA primary endpoint reflects the full constellation of nOH symptoms score Investigators and Site Selection Leading KOLs and many high - quality sites
Slide 11: Positioned to Capitalize Rapidly Upon Potential Positive Readout from Pivotal Phase 3 CYPRESS Trial
11 Positioned to Capitalize Rapidly Upon Potential Positive Readout from Pivotal Phase 3 CYPRESS Trial NDA, new drug application. If positive, incorporate CYPRESS data into NDA and request priority review Plan in place to support successful launch Alignment with FDA achieved; NDA preparations underw
Slide 12: Significant Commercial Opportunity for Ampreloxetine
12 Significant Commercial Opportunity for Ampreloxetine 1. Data from NYU Langone MSA Natural History Statistics, NYU September 2019. 2. Reflects Theravance Biopharma's expectations for ampreloxetine . Ampreloxetine is in development and not approved for any indication. No conclusion can be drawn reg
Slide 13: Milestones from Royalty Pharma
The First And Only Once - Daily Triple Therapy In a Single Inhaler For Adult Patients With COPD Or Asthma Milestones from Royalty Pharma Aziz Sawaf Senior Vice President, Chief Financial Officer GSK’s TRELEGY COPD, chronic obstructive pulmonary disease
Slide 14: On Pace to Achieve $150M in TRELEGY Sales Milestones in 2025 and 2026
14 On Pace to Achieve $150M in TRELEGY Sales Milestones in 2025 and 2026 Q2’25 Net Sales of $1.1B and YTD Net Sales of $2.0B, up 8% YoY 1. If both milestones are achieved in a given year, Theravance Biopharma will only earn the higher milestone, payable by Royalty Pharma (RP) pursuant to the Equity
Slide 15: Financial Update
Financial Update Aziz Sawaf Senior Vice President, Chief Financial Officer
Slide 16: Second Quarter 2025 Financials (Unaudited)
16 Second Quarter 2025 Financials (Unaudited) 1. Amounts include share - based compensation. 2. Non - GAAP net loss consists of GAAP net income (loss) before taxes excluding (i) share - based compensation expense; (ii) non - cash interest expense; (iii) non - cash impairment expense; and (iv) non -
Slide 17: Second Quarter 2025 Financials (Unaudited) (Cont'd)
17 Second Quarter 2025 Financials (Unaudited) (Cont’d) 17 See the section titled "Non - GAAP Financial Measures" on Slide 2 for more information. GAAP Net Income (Loss) $ 54,835 $ (16,529) $ 41,256 $ (28,193) Adjustments: Licensing revenue (1) (7,500) - (7,500) - Net gain on realized contingent mile
Slide 18: Second Quarter 2025 Financial Highlights
18 Second Quarter 2025 Financial Highlights 1. Non - GAAP net loss consists of GAAP net income (loss) before taxes less ( i ) share - based compensation expense; (ii) non - cash interest expense; (iii) non - cash impairment expense; and (iv) non - recurring revenue and income items; see reconciliati
Slide 19: Reiterating All Financial Guidance Metrics
19 1. Non - GAAP net loss consists of GAAP net income (loss) before taxes less ( i ) share - based compensation expense; (ii) non - cash interest expense; (iii) non - cash impairment expense; and (iv) non - recurring revenue and income items; see reconciliation on Slide 17 and the section titled "No
Slide 20: Strong Financial Position and Cash-Generating YUPELRI Set the Foundation for Near-Term Ampreloxetine Phase 3 Catalyst
20 Strong Financial Position and Cash - Generating YUPELRI ® Set the Foundation for Near - Term Ampreloxetine Phase 3 Catalyst 1. Kalra DK, et al. Clin Med Insights: Cardiol . 2020 (70% - 90%);14:1179546820953415. 2. Delveinsight MSA Market Forecast (2023); Symptoms associated with orthostatic hypot
Slide 21: Q&A Session
Rick Winningham Chief Executive Officer Aziz Sawaf, CFA Senior Vice President, Chief Financial Officer Rhonda Farnum Senior Vice President, Chief Business Officer Áine Miller Senior Vice President, Development Q&A Session
Slide 22: YUPELRI (revefenacin) Inhalation Solution Important Safety Information
22 YUPELRI ® (revefenacin) Inhalation Solution YUPELRI ® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) . Important Safety Information (US) YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any
Slide 23: About YUPELRI (revefenacin) Inhalation Solution
23 About YUPELRI ® (revefenacin) Inhalation Solution YUPELRI ® (revefenacin) inhalation solution is a once - daily nebulized LAMA approved for the maintenance treatment of COPD in the US . Market research by Theravance Biopharma indicates approximately 9 % of the treated COPD patients in the US use